<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "5: prescription volume", fill: "#fada5e"},
{source: "5: prescription volume", target: "5: products will continue", fill: "#fada5e"},
{source: "5: products will continue", target: "5: constitute", fill: "#fada5e"},
{source: "5: constitute", target: "5: significant", fill: "#fada5e"},
{source: "5: significant", target: "5: total revenues", fill: "#fada5e"},
{source: "5: total revenues", target: "5: foreseeable future", fill: "#fada5e"},
{source: "5: prescription volume", target: "6: Accordingly ", fill: "#8fbc8f"},
{source: "6: Accordingly ", target: "6: expectations", fill: "#8fbc8f"},
{source: "6: Accordingly ", target: "7: competition", fill: "#734f96"},
{source: "7: competition", target: "9: sales could also", fill: "#cd5700"},
{source: "9: sales could also", target: "9: adversely", fill: "#cd5700"},
{source: "9: adversely", target: "9: affected by", fill: "#cd5700"},
{source: "9: affected by", target: "9: manufacturing", fill: "#cd5700"},
{source: "9: manufacturing", target: "9: supply interruptions", fill: "#cd5700"},
{source: "9: supply interruptions", target: "9: development", fill: "#cd5700"},
{source: "9: development", target: "9: new competitive pharmaceuticals", fill: "#cd5700"},
{source: "9: new competitive pharmaceuticals", target: "9: conditions addressed by", fill: "#cd5700"},
{source: "9: conditions addressed by", target: "9: pricing actions by", fill: "#cd5700"},
{source: "9: pricing actions by", target: "9: competitors", fill: "#cd5700"},
{source: "9: competitors", target: "9: procedural practices", fill: "#cd5700"},
{source: "9: procedural practices", target: "9: dermatologists", fill: "#cd5700"},
{source: "9: dermatologists", target: "9: pediatricians", fill: "#cd5700"},
{source: "9: pediatricians", target: "9: reimbursement", fill: "#cd5700"},
{source: "9: reimbursement", target: "9: substitution policies", fill: "#cd5700"},
{source: "9: substitution policies", target: "9: thirdparty", fill: "#cd5700"},
{source: "9: thirdparty", target: "9: retail pharmacies", fill: "#cd5700"},
{source: "9: retail pharmacies", target: "9: federal law", fill: "#cd5700"},
{source: "9: federal law", target: "9: adversely affect", fill: "#cd5700"},
{source: "9: adversely affect", target: "9: dermatologists pediatricians", fill: "#cd5700"},
{source: "9: dermatologists pediatricians", target: "9: professionals", fill: "#cd5700"},
{source: "9: sales could also", target: "20: pursuing several", fill: "#00ced1"},
{source: "20: pursuing several", target: "20: international", fill: "#00ced1"},
{source: "20: international", target: "20: applications", fill: "#00ced1"},
{source: "20: applications", target: "20: patents will ever", fill: "#00ced1"},
{source: "20: pursuing several", target: "26: patent infringement lawsuit against", fill: "#138808"},
{source: "26: patent infringement lawsuit against", target: "26: Agis Industries ", fill: "#138808"},
{source: "26: Agis Industries ", target: "26: since been renamed", fill: "#138808"},
{source: "26: since been renamed", target: "26: Perrigo Israel ", fill: "#138808"},
{source: "26: Perrigo Israel ", target: "26: abbreviated new", fill: "#138808"},
{source: "26: abbreviated new", target: "26: drug application", fill: "#138808"},
{source: "26: drug application", target: "26: generic version", fill: "#138808"},
{source: "26: generic version", target: "26: clobetasol propionate", fill: "#138808"},
{source: "26: patent infringement lawsuit against", target: "29: challenges", fill: "#df00ff"},
{source: "29: challenges", target: "29: inherent costs", fill: "#df00ff"},
{source: "29: inherent costs", target: "29: technology", fill: "#df00ff"},
{source: "29: technology", target: "29: issued patents", fill: "#df00ff"},
{source: "29: issued patents", target: "29: prosecution", fill: "#df00ff"},
{source: "29: prosecution", target: "29: infringements", fill: "#df00ff"},
{source: "29: infringements", target: "29: litigation could", fill: "#df00ff"},
{source: "29: challenges", target: "33: may independently", fill: "#e5e4e2"},
{source: "33: may independently", target: "33: technologies", fill: "#e5e4e2"},
{source: "33: technologies", target: "33: design around", fill: "#e5e4e2"},
{source: "33: design around", target: "33: patented aspects", fill: "#e5e4e2"},
{source: "33: patented aspects", target: "33: technology", fill: "#e5e4e2"},
{source: "33: may independently", target: "36: unsuccessful", fill: "#b22222"},
{source: "36: unsuccessful", target: "36: technologies", fill: "#b22222"},
{source: "36: technologies", target: "36: cease marketing", fill: "#b22222"},
{source: "36: cease marketing", target: "36: challenged products", fill: "#b22222"},
{source: "36: challenged products", target: "36: avoid infringing upon", fill: "#b22222"},
{source: "36: unsuccessful", target: "56: technology candidates suitable", fill: "#bc987e"},
{source: "56: technology candidates suitable", target: "56: acquisition", fill: "#bc987e"},
{source: "56: acquisition", target: "56: suitable candidates", fill: "#bc987e"},
{source: "56: suitable candidates", target: "56: available on", fill: "#bc987e"},
{source: "56: technology candidates suitable", target: "87: payments on", fill: "#fc0fc0"},
{source: "87: payments on", target: "87: will depend on", fill: "#fc0fc0"},
{source: "87: will depend on", target: "87: sufficient cash which will depend on efficiently", fill: "#fc0fc0"},
{source: "87: sufficient cash which will depend on efficiently", target: "87: new products", fill: "#fc0fc0"},
{source: "87: new products", target: "87: significant", fill: "#fc0fc0"},
{source: "87: significant", target: "87: potential increasing sales", fill: "#fc0fc0"},
{source: "87: potential increasing sales", target: "87: products collecting receivables", fill: "#fc0fc0"},
{source: "87: products collecting receivables", target: "87: economic financial competitive legislative", fill: "#fc0fc0"},
{source: "87: economic financial competitive legislative", target: "87: regulatory conditions", fill: "#fc0fc0"},
{source: "87: regulatory conditions", target: "87: additional debt", fill: "#fc0fc0"},
{source: "87: additional debt", target: "87: equity financing on", fill: "#fc0fc0"},
{source: "87: payments on", target: "104: agreements will allow us", fill: "#3cb371"},
{source: "104: agreements will allow us", target: "104: pharmaceutical", fill: "#3cb371"},
{source: "104: agreements will allow us", target: "125: Pursuant ", fill: "#123524"},
{source: "125: Pursuant ", target: "125: distribution", fill: "#123524"},
{source: "125: distribution", target: "125: agreements", fill: "#123524"},
{source: "125: agreements", target: "125: Cardinal McKesson ", fill: "#123524"},
{source: "125: Cardinal McKesson ", target: "125: AmerisourceBergen ", fill: "#123524"},
{source: "125: Pursuant ", target: "START_HERE", fill: "#123524"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Ask for protection</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Decline comment</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Inflation">Inflation</a></td>
      <td>An infection is the invasion of an organism's body tissues by pathogens, their multiplication, and the reaction of host tissues to the infectious agents and the toxins they produce. An infectious disease, also known as a transmissible disease or communicable disease, is an illness resulting from an infection.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Textile_manufacturing">Textile manufacturing</a></td>
      <td>Textile manufacturing is a major industry. It is largely based on the conversion of fibre into yarn, then yarn into fabric.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Advanced_manufacturing">Advanced manufacturing</a></td>
      <td>Advanced manufacturing is the use of innovative technology to improve products or processes, with the relevant technology being described as "advanced," "innovative," or "cutting edge." Advanced manufacturing industries "increasingly integrate new innovative technologies in both products and processes. The rate of technology adoption and the ability to use that technology to remain competitive and add value to define the advanced manufacturing sector."Engineers globally have implemented a variety of advanced technologies to improve the efficacy and efficiency of critical parts, such as parts within high temperature engines or surgical equipment, such as utilizing advanced materials and miniaturizing critical parts.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Capitation_(healthcare)">Capitation (healthcare)</a></td>
      <td>Capitation is a payment arrangement for health care service providers. It pays a set amount for each enrolled person assigned to them, per period of time, whether or not that person seeks care.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fee_Reimbursement_Scheme_(Andhra_Pradesh)">Fee Reimbursement Scheme (Andhra Pradesh)</a></td>
      <td>The Fee Reimbursement Scheme (also known as the Post-matric Scholarship Scheme) is a student education sponsorship programme of the Government of Andhra Pradesh. It supports students from lower economic strata in the state.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacy">Pharmacy</a></td>
      <td>Pharmacy is the clinical health science that links medical science with chemistry and it is charged with the discovery, production, disposal, safe and effective use, and control of medications and drugs. The practice of pharmacy requires excellent knowledge of drugs, their mechanism of action, side effects, interactions, mobility and toxicity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Application_software">Application software</a></td>
      <td>An application program (application or app for short) is a computer program designed to carry out a specific task other than one relating to the operation of the computer itself, typically to be used by end-users. Word processors, media players, and accounting software are examples of.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/App_Store_(iOS/iPadOS)">App Store (iOS/iPadOS)</a></td>
      <td>The App Store is an app store platform, developed and maintained by Apple Inc., for mobile apps on its iOS and iPadOS operating systems. The store allows users to browse and download approved apps developed within Apple's iOS Software Development Kit.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mobile_app">Mobile app</a></td>
      <td>A mobile application or app is a computer program or software application designed to run on a mobile device such as a phone, tablet, or watch. Mobile applications often stand in contrast to desktop applications which are designed to run on desktop computers, and web applications which run in mobile web browsers rather than directly on the mobile device.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Application_security">Application security</a></td>
      <td>Application security (short AppSec) includes all tasks that introduce a secure software development life cycle to development teams. Its final goal is to improve security practices and, through that, to find, fix and preferably prevent security issues within applications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Teva_Pharmaceuticals">Teva Pharmaceuticals</a></td>
      <td>Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_product_development">New product development</a></td>
      <td>In business and engineering, new product development (NPD) covers the complete process of bringing a new product to market, renewing an existing product or introducing a product in a new market. A central aspect of NPD is product design, along with various business considerations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/High_availability">High availability</a></td>
      <td>High availability (HA) is a characteristic of a system which aims to ensure an agreed level of operational performance, usually uptime, for a higher than normal period.\nModernization has resulted in an increased reliance on these systems.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Available-to-promise">Available-to-promise</a></td>
      <td>Available-to-promise (ATP) is a business function that provides a response to customer order inquiries, based on resource availability.\n It generates available quantities of the requested product, and delivery due dates.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_innovation">Product innovation</a></td>
      <td>Product innovation is the creation and subsequent introduction of a good or service that is either new, or an improved version of previous goods or services. This is broader than the normally accepted definition of innovation that includes the invention of new products which, in this context, are still considered innovative.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Diversification_(marketing_strategy)">Diversification (marketing strategy)</a></td>
      <td>Diversification is a corporate strategy to enter into a new products or product lines, new services or new markets, involving substantially different skills, technology and knowledge.\nDiversification is one of the four main growth strategies defined by Igor Ansoff in the Ansoff Matrix:\nAnsoff pointed out that a diversification strategy stands apart from the other three strategies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutics">Pharmaceutics</a></td>
      <td>Pharmaceutics is the discipline of pharmacy that deals with the process of turning a new chemical entity (NCE) or old drugs into a medication to be used safely and effectively by patients.  It is also called the science of dosage form design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_code">Pharmaceutical code</a></td>
      <td>Pharmaceutical codes are used in medical classification to uniquely identify medication. They may uniquely identify an active ingredient, drug system (including inactive ingredients and time-release agents) in general, or a specific pharmaceutical product from a specific manufacturer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Janssen_Pharmaceuticals">Janssen Pharmaceuticals</a></td>
      <td>Janssen Pharmaceuticals is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson &amp; Johnson. It was founded in 1953 by Paul Janssen.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_microbiology">Pharmaceutical microbiology</a></td>
      <td>Pharmaceutical Microbiology is an applied branch of Microbiology.  It involves the study of microorganisms associated with the manufacture of pharmaceuticals e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Film_distribution">Film distribution</a></td>
      <td>Film distribution is the process of making a movie available for viewing by an audience. This is normally the task of a professional film distributor, who would determine the marketing strategy for the film, the media by which a film is to be exhibited or made available for viewing, and who may set the release date and other matters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Digital_distribution">Digital distribution</a></td>
      <td>Digital distribution (also referred to as content delivery, online distribution, or electronic software distribution (ESD), among others) is the delivery or distribution of digital media content such as audio, video, e-books, video games, and other software. The term is generally used to describe distribution over an online delivery medium, such as the Internet, thus bypassing physical distribution methods, such as paper, optical discs, and VHS videocassettes.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CONNETICS CORP      Item 1A Risk Factors              There  are many factors that affect our business and results of     <font color="blue">operations</font>, some of which are beyond our control</td>
    </tr>
    <tr>
      <td>We provide the following     discussion  of risks and <font color="blue">uncertainties relevant</font> to our business</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">factors could</font> cause our actual results to <font color="blue">differ <font color="blue">materially</font> from</font> expected     and historical results</td>
    </tr>
    <tr>
      <td>Risks Related to Our Business       We <font color="blue">derive nearly</font> all of our <font color="blue">revenue from <font color="blue">product sales</font></font>, and any decrease in     our <font color="blue"><font color="blue">product sales</font> would harm</font> our business</td>
    </tr>
    <tr>
      <td>We believe that the <font color="blue"><font color="blue">prescription</font> volume</font> of our <font color="blue">products <font color="blue">will continue</font></font>     to  <font color="blue">constitute</font>  a  <font color="blue">significant</font>  portion  of our <font color="blue">total revenues</font> for the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Accordingly, any decrease in our <font color="blue">product sales</font> would     harm our business and cause our financial results to be below <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>All of our products are subject to potential generic <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>Any of our     <font color="blue">products could</font> be rendered obsolete or uneconomical by <font color="blue">competitive</font> changes,     including  generic  <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">sales could also</font> be <font color="blue">adversely</font>     <font color="blue">affected by</font> other factors, including:         •  <font color="blue">manufacturing</font> or <font color="blue">supply <font color="blue">interruption</font>s</font>,         •  the <font color="blue">development</font> of new <font color="blue">competitive</font> <font color="blue">pharmaceutical</font>s to treat the     <font color="blue">conditions addressed by</font> our products,         •  marketing or <font color="blue">pricing actions by</font> our <font color="blue">competitors</font>,         •  changes in the prescribing or <font color="blue">procedural practices</font> of <font color="blue">dermatologists</font> or     <font color="blue">pediatricians</font>,         •  changes in the <font color="blue">reimbursement</font> or <font color="blue">substitution policies</font> of third-party     payors or <font color="blue">retail pharmacies</font>,         •  the outcome of disputes relating to patents, and         •  changes in state and <font color="blue">federal law</font> that <font color="blue">adversely</font> affect our ability to     market our products to <font color="blue">dermatologists</font>, <font color="blue">pediatricians</font>, and other healthcare     <font color="blue">professionals</font></td>
    </tr>
    <tr>
      <td>Our operating results <font color="blue">may fluctuate</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">fluctuation could</font> cause our     financial results to be below <font color="blue">expectations</font> and the <font color="blue"><font color="blue">market price</font>s</font> of our     securities to decline</td>
    </tr>
    <tr>
      <td>Our operating results <font color="blue">may fluctuate</font> from period to period for a number     of reasons, some of which are beyond our control</td>
    </tr>
    <tr>
      <td>Even a <font color="blue">relatively</font> small     revenue shortfall may cause a period’s results to be below our <font color="blue">expectations</font>     or <font color="blue">projections</font>, which in turn may cause the <font color="blue">market price</font> of our securities     to drop <font color="blue">significant</font>ly and the value of your <font color="blue">investment</font> to decline</td>
    </tr>
    <tr>
      <td>If we do not sustain <font color="blue">profitability</font>, stockholders may lose their <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Fiscal year 2004 was our <font color="blue">first year</font> of operating <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">accumulated</font>   deficit  was  dlra77dtta2 million  at  <font color="blue">December </font>31,  2005  and     dlra111dtta2 million at <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>We <font color="blue">may incur additional losses</font> in the     future</td>
    </tr>
    <tr>
      <td>If we are unable to sustain <font color="blue">profitability</font> during any quarterly or     <font color="blue">annual period</font>, our <font color="blue">stock price may decline</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial <font color="blue">success depend</font>s</font> in part on our ability and the ability of our     <font color="blue">licensors</font> to obtain and maintain <font color="blue">patent protection on <font color="blue">technologies</font></font>, to     <font color="blue">preserve <font color="blue">trade secrets</font></font>, and to operate <font color="blue">without infringing</font> the <font color="blue">proprietary</font>     rights of others</td>
    </tr>
    <tr>
      <td>We are <font color="blue">pursuing several</font> US and <font color="blue">international</font> patent <font color="blue"><font color="blue">application</font>s</font>,     although we cannot be sure that any of these <font color="blue">patents will ever</font> be issued</td>
    </tr>
    <tr>
      <td>We     also have acquired rights to patents and patent <font color="blue"><font color="blue">application</font>s</font> from certain of     our <font color="blue">consultants</font> and officers</td>
    </tr>
    <tr>
      <td>Any of our patents and patent <font color="blue"><font color="blue">application</font>s</font>     could be subject to                                         19       _________________________________________________________________    [97]Table <font color="blue">of <font color="blue">Contents       </font></font>claims of <font color="blue">rights by <font color="blue">third parties</font></font></td>
    </tr>
    <tr>
      <td>Even if we do have some rights in a     patent or <font color="blue">application</font>, those <font color="blue">rights may</font> not be sufficient for marketing and     <font color="blue">distributing products covered by</font> the patent or <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>The patents and <font color="blue"><font color="blue">application</font>s</font> in which we have an <font color="blue">interest may</font> be     <font color="blue">challenged as</font> to their validity or <font color="blue">enforceability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Challenges </font>may result in     potentially <font color="blue">significant</font> harm to our business</td>
    </tr>
    <tr>
      <td>On October 20, 2005, we filed     a <font color="blue">patent infringement lawsuit against</font> <font color="blue">Agis Industries </font>(1983) Ltd, which has     <font color="blue">since been renamed</font> Perrigo Israel, a wholly owned subsidiary of Perrigo     Company, in response to Agis’s submission to the FDA of an <font color="blue">abbreviated new</font>     drug <font color="blue">application</font>, or ANDA, for a <font color="blue">generic version</font> of <font color="blue">clobetasol propionate</font>     foam,  0dtta05prca</td>
    </tr>
    <tr>
      <td>We market this <font color="blue">drug product under</font> the brand name OLUX^®     (<font color="blue">clobetasol propionate</font>) Foam 0dtta05prca</td>
    </tr>
    <tr>
      <td>Our lawsuit, filed in the US District     Court for the District of New Jersey, seeks, among other things, a finding     that  Agis’s  proposed  generic  drug  infringes  our  <font color="blue">patent covering</font>     <font color="blue">corticosteroids</font> delivered in foam, and requests that any approval of the     <font color="blue">Agis ANDA </font>not be declared <font color="blue"><font color="blue">effective</font> until</font> after this <font color="blue">patent expires on</font>     March 2, 2016</td>
    </tr>
    <tr>
      <td>The cost of responding to this and other similar <font color="blue">challenges</font> that may     arise  and  the  <font color="blue">inherent costs</font> to defend the validity of our licensed     <font color="blue">technology</font> and <font color="blue">issued patents</font>, including the <font color="blue">prosecution</font> of <font color="blue">infringements</font>     and the related litigation, could be substantial whether or not we are     successful</td>
    </tr>
    <tr>
      <td>Such <font color="blue">litigation also could</font> require a substantial <font color="blue">commitment</font> of     <font color="blue">management</font>’s time</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">could suffer <font color="blue">materially</font></font> if any <font color="blue">third party</font>     were to be awarded a <font color="blue">judgment adverse</font> to us in any patent litigation or     other proceeding arising in <font color="blue"><font color="blue">connection</font> with</font> any of our products or patent     <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>The ownership of a patent or an interest in a patent does not always     provide <font color="blue">significant</font> protection</td>
    </tr>
    <tr>
      <td>Others <font color="blue">may <font color="blue">independent</font>ly</font> develop similar     <font color="blue">technologies</font> or <font color="blue">design around</font> the <font color="blue">patented aspects</font> of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">only conduct patent searches</font> to determine whether our <font color="blue">products infringe upon</font>     any <font color="blue">existing patents</font> when we think <font color="blue">such searches</font> are <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>As a     result, the products and <font color="blue">technologies</font> we currently market, and those we may     market in the future, may infringe on patents and other rights owned by     others</td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in any challenge to the marketing and sale of     our products or <font color="blue">technologies</font>, we may be required to license the disputed     rights, if the holder of those rights is willing, or to <font color="blue">cease marketing</font> the     <font color="blue">challenged products</font>, or to modify our products to <font color="blue">avoid infringing upon</font>     those rights</td>
    </tr>
    <tr>
      <td>Under these <font color="blue">circumstances</font>, we may not be able to license the     <font color="blue">intellectual property on</font> favorable terms, if at all</td>
    </tr>
    <tr>
      <td>We may not succeed in     any attempt to redesign our products or processes to <font color="blue">avoid infringement</font></td>
    </tr>
    <tr>
      <td><font color="blue">Evoclin Foam </font><font color="blue">represents</font> a <font color="blue">new product entry</font> for us into the <font color="blue">acne market</font> and     we may be unable to achieve desired <font color="blue">market <font color="blue">acceptance</font></font> and sales of Evoclin     Foam</td>
    </tr>
    <tr>
      <td>The FDA approved <font color="blue">Evoclin Foam </font>in October 2004 for the treatment of     <font color="blue">acne vulgaris</font></td>
    </tr>
    <tr>
      <td>It is our <font color="blue">first product entry into</font> the <font color="blue">acne market</font>, which is     <font color="blue">generally</font>  believed  to  be more <font color="blue">competitive</font> than the market for other     <font color="blue">dermatoses</font></td>
    </tr>
    <tr>
      <td>We will not be able to achieve the desired <font color="blue">market <font color="blue">acceptance</font></font> and     sales of <font color="blue">Evoclin Foam </font>unless our marketing and <font color="blue">sales strategy</font> is <font color="blue">effective</font>     in <font color="blue">competing with existing</font> and <font color="blue">well established products</font> in the <font color="blue">acne market</font></td>
    </tr>
    <tr>
      <td>Additionally, the commercial launch of <font color="blue">Evoclin Foam </font>has required and, we     anticipate, <font color="blue">will continue</font> to require <font color="blue">significant</font> expenditures of <font color="blue">management</font>     time and <font color="blue">resources from which</font> we may not realize anticipated returns</td>
    </tr>
    <tr>
      <td>Our <font color="blue">total revenue depends on</font> receiving royalties and <font color="blue">contract payments from</font>     <font color="blue">third parties</font>, and we <font color="blue">cannot control</font> the amount or timing of those revenues</td>
    </tr>
    <tr>
      <td>We <font color="blue">generate contract</font> and <font color="blue"><font color="blue">royalty revenues</font> by licensing</font> our products to     <font color="blue">third parties</font> for <font color="blue">specific territories</font> and <font color="blue">indications</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font>     licensing arrangements with <font color="blue">third parties</font> carries <font color="blue">several risks</font>, including     the <font color="blue">possibilities</font> that:         •  royalties generated from licensing arrangements may be in<font color="blue">significant</font> or     <font color="blue">may fluctuate</font> from period to period, and         •  a loss of <font color="blue">royalties could</font> have a <font color="blue">disproportionately</font> large <font color="blue">impact on</font> our     operating income in periods where the operating income is a small profit</td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________    [98]Table <font color="blue">of <font color="blue">Contents       </font></font>We rely on our employees and <font color="blue">consultants</font> to keep our <font color="blue">trade secrets</font>     <font color="blue">confidential</font></td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">trade secrets</font> and unpatented <font color="blue">proprietary</font> know-how and     <font color="blue">continuing technological innovation</font> in developing and <font color="blue">manufacturing</font> our     products</td>
    </tr>
    <tr>
      <td>We require each of our employees, <font color="blue">consultants</font>, <font color="blue">manufacturing</font>     partners, and advisors to <font color="blue">enter into</font> <font color="blue">confidential</font>ity <font color="blue">agreements</font> prohibiting     them from taking our <font color="blue">proprietary</font> information and <font color="blue">technology</font> or from using or     disclosing <font color="blue">proprietary</font> information to <font color="blue">third parties</font> except in specified     <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">agreements</font> may</font> not <font color="blue">provide meaningful protection</font> of our     <font color="blue">trade secrets</font> and <font color="blue">proprietary</font> know-how that is used or disclosed</td>
    </tr>
    <tr>
      <td><font color="blue">Despite     </font>all  of  the  <font color="blue">precautions</font>  we  may take, people who are not parties to     <font color="blue">confidential</font>ity  <font color="blue">agreements</font>  may obtain access to our <font color="blue">trade secrets</font> or     know-how</td>
    </tr>
    <tr>
      <td>In  addition,  others  <font color="blue">may <font color="blue">independent</font>ly</font> develop similar or     equivalent <font color="blue">trade secrets</font> or know-how</td>
    </tr>
    <tr>
      <td>The growth of our business depends in part on our ability to identify,     acquire on favorable terms, and assimilate <font color="blue">technologies</font>, products or     <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Our strategy for the <font color="blue">continuing growth</font> of our business includes     identifying and acquiring strategic <font color="blue">pharmaceutical</font> products, <font color="blue">technologies</font>     and <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">acquisition</font>s may involve licensing</font> or purchasing the     assets of other <font color="blue"><font color="blue">pharmaceutical</font> companies</font></td>
    </tr>
    <tr>
      <td>We may not be able to identify     product or <font color="blue">technology</font> <font color="blue">candidates</font> suitable for <font color="blue">acquisition</font> or licensing or,     if  we  do  identify <font color="blue">suitable <font color="blue">candidates</font></font>, they may not be <font color="blue">available on</font>     acceptable  terms</td>
    </tr>
    <tr>
      <td>Even if we are able to identify <font color="blue">suitable product</font> or     <font color="blue">technology</font> <font color="blue">candidates</font>, acquiring or <font color="blue">licensing them may</font> require us to make     considerable  cash  outlays,  issue  equity securities, incur debt and     contingent <font color="blue">liabilities</font>, incur amortization expenses related to intangible     assets, and can result in the <font color="blue">impairment</font> of goodwill, <font color="blue">which could</font> harm our     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In  addition,  <font color="blue">acquisition</font>s involve a number of risks,     including:         •  <font color="blue"><font color="blue">difficult</font>ies</font> in and <font color="blue">costs associated with assimilating</font> the <font color="blue">operations</font>,     <font color="blue">technologies</font>, personnel and products of the acquired companies,         •  <font color="blue">assumption</font> of known or <font color="blue">unknown <font color="blue">liabilities</font></font> or other <font color="blue">unanticipated</font>     events or <font color="blue">circumstances</font>, and         •  risks of <font color="blue">entering markets</font> in which we have limited or no experience</td>
    </tr>
    <tr>
      <td>For example, while the <font color="blue">acquisition</font> of the PediaMed <font color="blue">sales organization will</font>     <font color="blue">greatly expand</font> our presence in the <font color="blue">pediatric market</font>, we cannot be certain     <font color="blue">pediatricians</font> will respond favorably to our <font color="blue">direct promotional efforts</font></td>
    </tr>
    <tr>
      <td>Any of these risks could harm our ability to achieve levels of <font color="blue">profitability</font>     of  acquired <font color="blue">operations</font> or to realize other anticipated benefits of an     <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future <font color="blue">product revenues</font> could</font> be <font color="blue">reduced by imports from countries</font> where     our products are <font color="blue">available at lower prices</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently sell</font> Soriatane and our other products to a     US-based <font color="blue">distributor</font> that <font color="blue">exports branded <font color="blue">pharmaceutical</font> products</font> to     select <font color="blue">international</font> markets</td>
    </tr>
    <tr>
      <td>A has exclusive rights to market and sell     OLUX in Italy and the UK, and Pierre Fabre Dermatologie has the exclusive     <font color="blue">commercial rights</font> to OLUX for sale in all <font color="blue">other European </font>markets, with     <font color="blue">marketing rights</font> for <font color="blue">certain countries</font> in <font color="blue">South America and Africa</font></td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>have  been cases in <font color="blue">which <font color="blue">pharmaceutical</font> products</font> were <font color="blue">sold at steeply</font>     discounted prices in <font color="blue">markets outside</font> the US and then re-imported to the     US and resold at prices higher than the original discounted price, but     lower than the prices <font color="blue">commercially</font> available <font color="blue">in the US If </font>this happens     with our products our <font color="blue">revenues would</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>In  addition,  in the European Union, we are required to permit     cross-border   sales</td>
    </tr>
    <tr>
      <td>This   allows   buyers   in   countries  where     government-approved prices for our products are <font color="blue">relatively</font> high to purchase     our <font color="blue">products legally from countries</font> where they must be <font color="blue">sold at lower prices</font></td>
    </tr>
    <tr>
      <td>Such cross-border sales could <font color="blue">adversely</font> affect our <font color="blue">royalty revenues</font></td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________    [99]Table <font color="blue">of <font color="blue">Contents       </font></font>Our reported <font color="blue">earnings per</font> share may be more volatile because of the     <font color="blue"><font color="blue">conversion</font> provisions</font> of our <font color="blue">convertible senior</font> notes or the exercise of     <font color="blue">outstanding stock options</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">noteholders</font> may convert</font> the notes     into shares of our <font color="blue"><font color="blue">common stock</font> at</font> any time before the notes mature, at a     <font color="blue"><font color="blue">conversion</font> rate</font> of 46dtta705 shares per dlra1cmam000 principal amount of notes,     subject to <font color="blue">adjustment</font> in certain <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>Additionally, in March 2005,     we issued dlra200 million principal amount of <font color="blue">convertible senior</font> notes due in     2015, which are <font color="blue">convertible into cash</font> and, under certain <font color="blue">circumstances</font>,     shares of our <font color="blue"><font color="blue">common stock</font> at</font> an initial <font color="blue"><font color="blue">conversion</font> rate</font> of 28dtta1972 shares     per dlra1cmam000 principal amount of notes, subject to <font color="blue">adjustment</font></td>
    </tr>
    <tr>
      <td>At <font color="blue">December </font>31,     2005 we had approximately 20 million shares reserved for <font color="blue">issuance upon</font>     exercise of <font color="blue">outstanding stock options</font>, sales through our Employee Stock     Purchase  Plan, and <font color="blue">conversion</font> of our <font color="blue">convertible senior</font> notes</td>
    </tr>
    <tr>
      <td>If any     <font color="blue">noteholders</font> convert the notes, or if our option holders exercise their     options, our basic <font color="blue">earnings per</font> share would be expected to decrease because     underlying  shares  would  be included in the basic <font color="blue">earnings per</font> share     <font color="blue">calculation</font></td>
    </tr>
    <tr>
      <td>Our current and <font color="blue">future indebtedness</font> and <font color="blue">debt service obligations may</font>     <font color="blue">adversely</font> affect our <font color="blue">cash flow</font></td>
    </tr>
    <tr>
      <td>In May 2003 we issued dlra90 million of <font color="blue">convertible senior</font> notes in a     <font color="blue">private offering</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">will pay <font color="blue">interest on</font></font> the notes at a rate of 2dtta25prca per     year</td>
    </tr>
    <tr>
      <td>In both 2004 and 2005, we recorded dlra2 million in <font color="blue">interest on</font> the     notes</td>
    </tr>
    <tr>
      <td>In March 2005 we issued dlra200 million principal amount of convertible     senior notes <font color="blue">maturing on</font> March 30, 2015</td>
    </tr>
    <tr>
      <td><font color="blue">On September </font>30, 2005, we began     paying  interest  on  these notes at a rate of 2dtta00prca per year</td>
    </tr>
    <tr>
      <td>Through     <font color="blue">December </font>31,  2005, we recorded <font color="blue">interest on</font> the notes in the amount of     dlra3dtta1 million</td>
    </tr>
    <tr>
      <td>Assuming none of these notes are redeemed or converted, we     will record <font color="blue">interest on</font> the notes in the amount of dlra4 million for years 2006     through 2009, and dlra1 million for 2010</td>
    </tr>
    <tr>
      <td><font color="blue">Commencing March </font>30, 2010, we may be     required to make additional interest payments under certain <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>Whether we are able to make required <font color="blue">payments on</font> the existing notes,     and any other future debt obligations we may incur in order to continue the     growth  of  our  business,  <font color="blue">will <font color="blue">depend on</font></font> (a) our ability to generate     sufficient cash, which <font color="blue">will <font color="blue">depend on</font></font> efficiently developing <font color="blue">new products</font>     with  <font color="blue">significant</font>  market  potential, increasing sales of our existing     products, collecting receivables, and other factors, including general     economic, financial, <font color="blue">competitive</font>, <font color="blue">legislative</font> and <font color="blue"><font color="blue">regulatory</font> conditions</font>,     some  of  which  are  beyond our control; and (b) our future operating     performance and our ability to obtain <font color="blue">additional debt</font> or <font color="blue">equity financing on</font>     favorable terms</td>
    </tr>
    <tr>
      <td>Our use of <font color="blue"><font color="blue">hazardous</font> materials exposes us</font> to the risk of <font color="blue">environmental</font>     <font color="blue">liabilities</font>, and we may incur substantial <font color="blue">additional costs</font> to <font color="blue">comply with</font>     <font color="blue">environmental</font> laws</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> activities involve the <font color="blue">controlled use</font> of     <font color="blue">hazardous</font> materials, potent compounds, chemicals and <font color="blue">various radioactive</font>     materials</td>
    </tr>
    <tr>
      <td>We  are subject to laws and <font color="blue"><font color="blue">regulations</font> governing</font> the use,     storage,  handling  and  disposal of these materials and <font color="blue">certain waste</font>     products</td>
    </tr>
    <tr>
      <td>If any of these materials resulted in <font color="blue">contamination</font> or injury, we     could be liable for any damages that result and any <font color="blue"><font color="blue">liability</font> could exceed</font>     our resources</td>
    </tr>
    <tr>
      <td>We maintain <font color="blue">general <font color="blue">liability</font> insurance</font> in the amount of     dlra11 million aggregate and <font color="blue">workers compensation coverage</font> in the amount of     dlra1 million per incident</td>
    </tr>
    <tr>
      <td>Our <font color="blue">insurance may</font> not <font color="blue">provide adequate coverage</font>     against  potential  claims  or  losses related to our use of <font color="blue">hazardous</font>     materials, however, and we cannot be certain that our <font color="blue">current coverage will</font>     continue to be <font color="blue">available on</font> reasonable terms, if at all</td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________    [100]Table <font color="blue">of <font color="blue">Contents       </font></font>Risks Related to Our Products       Because we rely on third-party <font color="blue">manufacture</font>rs and suppliers, any     <font color="blue">manufacturing</font> <font color="blue"><font color="blue">difficult</font>ies</font> they <font color="blue">encounter could delay future revenues from</font>     our <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>We rely exclusively on <font color="blue">third party</font> <font color="blue">manufacture</font>rs to <font color="blue">manufacture</font> our     products</td>
    </tr>
    <tr>
      <td>In general, our contract <font color="blue">manufacture</font>rs purchase principal raw     materials and supplies in the <font color="blue">open market</font></td>
    </tr>
    <tr>
      <td>If our contract <font color="blue">manufacture</font>rs     cannot  provide  us  with  our  product  <font color="blue">requirements</font>  in a timely and     cost-<font color="blue">effective</font>  manner,  or  if  the product they supply does not meet     commercial <font color="blue">requirements</font> for shelf life, our sales of <font color="blue"><font color="blue">marketed products</font> could</font>     be  reduced</td>
    </tr>
    <tr>
      <td>Currently, DPT Laboratories, Ltd</td>
    </tr>
    <tr>
      <td>and <font color="blue">KIK Custom Products     </font>(formerly Accra Pac Group, Inc</td>
    </tr>
    <tr>
      <td>) <font color="blue">manufacture</font> <font color="blue">commercial supplies</font> of OLUX     Foam, Luxiq Foam, and Evoclin Foam</td>
    </tr>
    <tr>
      <td>Roche is our sole <font color="blue">manufacture</font>r for     <font color="blue">commercial supplies</font> of Soriatane</td>
    </tr>
    <tr>
      <td>The active ingredient in OLUX Foam is <font color="blue">supplied by</font> a <font color="blue">single source</font></td>
    </tr>
    <tr>
      <td>We     have <font color="blue">agreements</font> with Roche to fill and finish Soriatane through 2006, and to     provide the <font color="blue">active <font color="blue">pharmaceutical</font></font> ingredient through 2009</td>
    </tr>
    <tr>
      <td>We believe that     these <font color="blue">agreements</font> will allow us to maintain supplies of Soriatane finished     product  through  2015  due  to the five-year shelf life of the active     <font color="blue">pharmaceutical</font>  ingredient</td>
    </tr>
    <tr>
      <td>We <font color="blue">will continue</font> to buy Soriatane finished     product and <font color="blue">active <font color="blue">pharmaceutical</font></font> ingredient from Roche, and we expect to     qualify  alternate  sources  for  <font color="blue">Soriatane  </font>finished product in 2007</td>
    </tr>
    <tr>
      <td><font color="blue">Substantially  </font>all  other <font color="blue">raw materials</font> are <font color="blue">available from</font> a number of     sources, although delays in the <font color="blue">availability</font> of some <font color="blue">raw materials</font> could     cause delays in our <font color="blue"><font color="blue">commercial product</font>ion</font></td>
    </tr>
    <tr>
      <td>If we are unable to maintain <font color="blue">agreements</font> on favorable terms with any of     our contract <font color="blue">manufacture</font>rs, or if we experience any <font color="blue">disruption</font> in the supply     of <font color="blue">raw materials</font> required for the <font color="blue">manufacture</font> of our products, it could     impair our ability to deliver our <font color="blue">products on</font> a <font color="blue">timely basis</font> or cause delays     in our <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue"><font color="blue">application</font>s</font> for <font color="blue"><font color="blue"><font color="blue">regulatory</font> approvals</font> which</font> in     turn would harm our business and financial results</td>
    </tr>
    <tr>
      <td>In addition, any loss of     a <font color="blue">manufacture</font>r or any <font color="blue"><font color="blue">difficult</font>ies</font> that could arise in the <font color="blue">manufacturing</font>     process could <font color="blue">significant</font>ly affect our <font color="blue">inventories</font> and supply of products     available for sale</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">supply sufficient amounts</font> of our     products  on  a  timely  basis,  our  market share <font color="blue">could decrease</font> and,     <font color="blue">correspondingly</font>, our <font color="blue">profitability</font> <font color="blue">could decrease</font></td>
    </tr>
    <tr>
      <td>If our contract <font color="blue">manufacture</font>rs fail to <font color="blue">comply with</font> FDA GMP <font color="blue">regulations</font>, we     may be unable to meet demand for our products and <font color="blue">may lose potential</font>     revenue</td>
    </tr>
    <tr>
      <td>All of our contract <font color="blue">manufacture</font>rs must <font color="blue">comply with</font> the applicable FDA     Good Manufacturing Practices, or GMP, <font color="blue">regulations</font>, which include quality     control and quality assurance <font color="blue">requirements</font> as well as maintaining records     and <font color="blue">documentation</font></td>
    </tr>
    <tr>
      <td>If our contract <font color="blue">manufacture</font>rs do not <font color="blue">comply with</font> the     applicable GMP <font color="blue">regulations</font> and other FDA <font color="blue">regulatory</font> <font color="blue">requirements</font>, both the     <font color="blue">availability</font> of <font color="blue">marketed products</font> for sale and product for <font color="blue"><font color="blue">clinical trial</font>s</font>     could be reduced</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">interruption</font> insurance, which covers the loss     of income for up to dlra14dtta1 million at our <font color="blue">California and Australia </font>locations,     and  dlra25dtta7 million  for our contract <font color="blue">manufacture</font>rs, may not <font color="blue">completely</font>     mitigate the harm to our business from the <font color="blue">interruption</font> of the <font color="blue">manufacturing</font>     of products</td>
    </tr>
    <tr>
      <td>The loss of a <font color="blue">manufacture</font>r could still have a negative effect     on our sales, margins and market share, as well as our overall business and     financial results</td>
    </tr>
    <tr>
      <td>If our supply of finished products is <font color="blue">interrupted</font>, our ability to maintain     our <font color="blue"><font color="blue">inventory levels</font> could suffer</font> and <font color="blue">future revenues may</font> be delayed</td>
    </tr>
    <tr>
      <td>We try to maintain <font color="blue">inventory levels</font> that are <font color="blue">no greater than necessary</font>     to meet our current <font color="blue">projections</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">interruption</font> in the supply of finished     <font color="blue">products could</font> hinder our ability to <font color="blue">timely distribute</font> finished products</td>
    </tr>
    <tr>
      <td>If     we  are  unable  to  obtain  adequate  <font color="blue">product supplies</font> to satisfy our     customers’ orders, we may lose those orders and our <font color="blue">customers may cancel</font>     other orders and stock and <font color="blue">sell competing products</font></td>
    </tr>
    <tr>
      <td>This in turn could cause     a loss of our market share and <font color="blue">negatively</font> affect our revenues</td>
    </tr>
    <tr>
      <td><font color="blue">Numerous     </font><font color="blue">factors could</font> cause <font color="blue">interruption</font>s in the supply of our finished products,     including shortages in raw material required by our <font color="blue">manufacture</font>rs, changes     in our sources for <font color="blue">manufacturing</font>, our failure to <font color="blue">timely locate</font> and obtain     replacement <font color="blue">manufacture</font>rs as needed, and <font color="blue">conditions affecting</font> the cost and     <font color="blue">availability</font> of <font color="blue">raw materials</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>increases and <font color="blue">decreases</font> in     <font color="blue">orders from</font> our <font color="blue"><font color="blue">major customers</font> could</font> cause our operating results to vary     <font color="blue">significant</font>ly from quarter to quarter</td>
    </tr>
    <tr>
      <td>Retail  <font color="blue">availability</font> of our products is greatly <font color="blue">affected by</font> the     <font color="blue">inventory levels</font> our customers hold</td>
    </tr>
    <tr>
      <td>We <font color="blue">monitor wholesaler inventory</font> of our     <font color="blue">products using</font> a <font color="blue">combination</font> of methods, including information <font color="blue">provided by</font>     the customers as well as tracking <font color="blue">prescription</font>s filled at the <font color="blue">pharmacy level</font>     to determine amounts the <font color="blue">wholesalers</font> have sold to their customers</td>
    </tr>
    <tr>
      <td><font color="blue">Pursuant     </font>to  our  <font color="blue">distribution</font>  service  <font color="blue">agreements</font> with Cardinal, McKesson and     AmerisourceBergen,  we  receive  inventory  level  reports</td>
    </tr>
    <tr>
      <td>For other     <font color="blue">wholesalers</font>, however, our estimates of wholesaler <font color="blue">inventories</font> may differ     <font color="blue">significant</font>ly from actual <font color="blue">inventory levels</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">differences between</font>     actual and estimated <font color="blue">inventory levels</font> may result in <font color="blue">excessive inventory</font>     production,  inadequate supplies of products in <font color="blue">distribution</font> channels,     insufficient or <font color="blue">excess product available at</font> the <font color="blue">retail level</font>, and unexpected     increases or <font color="blue">decreases</font> in <font color="blue">orders from</font> our <font color="blue">major customers</font></td>
    </tr>
    <tr>
      <td>These changes may     cause our revenues to fluctuate <font color="blue">significant</font>ly from quarter to quarter, and     in some <font color="blue">cases may</font> cause our operating results for a <font color="blue">particular quarter</font> to be     below our <font color="blue">expectations</font> or <font color="blue">projections</font></td>
    </tr>
    <tr>
      <td>If our financial results are below     <font color="blue">expectations</font> for a <font color="blue">particular period</font>, the <font color="blue">market price</font> of our <font color="blue">securities may</font>     drop <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot sell</font> our <font color="blue">current products</font> and <font color="blue">product <font color="blue">candidates</font></font> if we do not     obtain and maintain <font color="blue">governmental approvals</font></td>
    </tr>
    <tr>
      <td><font color="blue">Pharmaceutical </font>companies are subject to <font color="blue">heavy regulation by</font> a number     of national, state and <font color="blue">local agencies</font></td>
    </tr>
    <tr>
      <td>Of <font color="blue">particular importance</font> is the FDA     The  FDA  has  <font color="blue">jurisdiction</font>  over  all of our business and <font color="blue">administers</font>     <font color="blue">requirements</font> covering testing, <font color="blue">manufacture</font>, safety, <font color="blue">effective</font>ness, labeling,     storage,  record  keeping,  approval, <font color="blue">advertising</font> and promotion of our     products</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> applicable <font color="blue">regulatory</font> <font color="blue">requirements</font>, we     could be subject to fines, <font color="blue">suspensions</font> of <font color="blue"><font color="blue">regulatory</font> approvals</font> of products,     product recalls, delays in product <font color="blue">distribution</font>, marketing and sale, and     civil or <font color="blue">criminal sanctions</font></td>
    </tr>
    <tr>
      <td>The process of obtaining and maintaining <font color="blue"><font color="blue">regulatory</font> approvals</font> for     <font color="blue">pharmaceutical</font> products, and obtaining and maintaining <font color="blue"><font color="blue">regulatory</font> approvals</font>     to market these products for new <font color="blue">indications</font>, is lengthy, expensive and     uncertain</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacturing</font> and marketing of drugs, including our products,     are subject to continuing FDA and foreign <font color="blue">regulatory</font> review, and later     <font color="blue">discovery</font> of <font color="blue">previously</font> unknown problems with a product, <font color="blue">manufacturing</font>     process  or  <font color="blue">facility</font>  may result in <font color="blue">restrictions</font>, including recall or     withdrawal of the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>The FDA is permitted to revisit     and change its <font color="blue">prior determinations</font> and it may change its <font color="blue">position with</font>     regard to the safety or <font color="blue">effective</font>ness of our products</td>
    </tr>
    <tr>
      <td>Even before any     formal <font color="blue">regulatory</font> action, we <font color="blue">could voluntarily decide</font> to cease <font color="blue">distribution</font>     and  sale  or  recall  any of our products if <font color="blue">concerns about safety</font> or     <font color="blue">effective</font>ness develop</td>
    </tr>
    <tr>
      <td>In its regulation of <font color="blue">advertising</font>, the FDA from time to time issues     <font color="blue">correspondence</font> to <font color="blue"><font color="blue">pharmaceutical</font> companies</font> alleging that some <font color="blue">advertising</font> or     <font color="blue">promotional practices</font> are false, misleading or <font color="blue">deceptive</font></td>
    </tr>
    <tr>
      <td>The FDA has the     power to impose a <font color="blue">wide array</font> of <font color="blue">sanctions on companies</font> for such <font color="blue">advertising</font>     practices, and if we were to receive <font color="blue">correspondence</font> from the FDA alleging     these practices we might be required to:         •  change our methods of marketing and <font color="blue">selling products</font>,         •  take FDA-mandated corrective action, <font color="blue">which could</font> include placing     <font color="blue">advertisements</font> or <font color="blue">sending letters</font> to <font color="blue">physicians rescinding previous</font>     <font color="blue">advertisements</font> or promotion,         •  incur substantial expenses, including fines, penalties, legal fees and     costs to <font color="blue">comply with</font> the FDA’s <font color="blue">requirements</font>,         •  disrupt the <font color="blue">distribution</font> of products and <font color="blue">stop sales until</font> we are in     <font color="blue">compliance with</font> the FDA’s position</td>
    </tr>
    <tr>
      <td>24       _________________________________________________________________    [102]Table <font color="blue">of <font color="blue">Contents       </font></font>We may spend a <font color="blue">significant</font> amount of money to obtain FDA and other     <font color="blue"><font color="blue">regulatory</font> approvals</font>, which may never be granted</td>
    </tr>
    <tr>
      <td>Failure to obtain such     <font color="blue"><font color="blue">regulatory</font> approvals</font> could <font color="blue">adversely</font> affect our prospects for future revenue     growth</td>
    </tr>
    <tr>
      <td><font color="blue">Successful </font>product <font color="blue">development</font> in our industry is <font color="blue">highly uncertain</font>,     and the process of obtaining FDA and other <font color="blue"><font color="blue">regulatory</font> approvals</font> is lengthy     and  expensive</td>
    </tr>
    <tr>
      <td>Very  few research and <font color="blue">development</font> projects produce a     <font color="blue">commercial product</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">candidates</font> that appear promising in the early     phases of <font color="blue">development</font> may fail to reach the market for a number of reasons,     including that the <font color="blue">product candidate</font> did not <font color="blue">demonstrate</font> acceptable clinical     trial results in <font color="blue">humans even though</font> it <font color="blue">demonstrate</font>d positive preclinical     trial results, or that the <font color="blue">product candidate</font> was not <font color="blue">effective</font> in treating a     <font color="blue">specified condition</font> or illness</td>
    </tr>
    <tr>
      <td>The FDA may also require <font color="blue">additional clinical</font>     data to <font color="blue">support approval</font></td>
    </tr>
    <tr>
      <td>The FDA can take <font color="blue">between one</font> and two years to     review new drug <font color="blue"><font color="blue">application</font>s</font>, or longer if <font color="blue">significant</font> questions arise     during the <font color="blue">review process</font></td>
    </tr>
    <tr>
      <td>Moreover, the costs to obtain approvals could be     considerable and the failure to obtain, or delays in obtaining, an approval     could have a <font color="blue">significant</font> negative effect on our business</td>
    </tr>
    <tr>
      <td>For example, in     November 2004, the FDA notified us that it would not approve our NDA for     <font color="blue">Extina Foam </font><font color="blue">based on</font> its <font color="blue">conclusion</font> that, although <font color="blue">Extina Foam </font><font color="blue">demonstrate</font>d     non-inferiority to the <font color="blue">comparator drug currently on</font> the market, it did not     <font color="blue">demonstrate</font>  statistically <font color="blue">significant</font> superiority to <font color="blue">placebo foam</font></td>
    </tr>
    <tr>
      <td>In     addition, on June 10, 2005, the FDA issued a non-approvable letter for Velac     Gel, citing that “a positive <font color="blue">carcinogenicity signal</font> was detected in a Tg</td>
    </tr>
    <tr>
      <td>AC     <font color="blue">mouse dermal carcinogenicity study</font></td>
    </tr>
    <tr>
      <td>”       We <font color="blue">depend on</font> a limited number of customers, and if we lose any of them, our     business could be harmed</td>
    </tr>
    <tr>
      <td>Our customers include the nation’s leading wholesale <font color="blue">pharmaceutical</font>     <font color="blue">distributor</font>s,  such  as Cardinal Health, Inc, McKesson HBOC, Inc</td>
    </tr>
    <tr>
      <td>During  2005,  McKesson,  Cardinal,     AmerisourceBergen accounted for 36prca, 34prca, and 11prca, respectively, of our net     <font color="blue">product revenues</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">distribution</font> network for <font color="blue">pharmaceutical</font> products is     subject to <font color="blue">increasing <font color="blue">consolidation</font></font>, and a few large wholesale <font color="blue">distributor</font>s     control  a <font color="blue">significant</font> share of the market</td>
    </tr>
    <tr>
      <td>In addition, the number of     <font color="blue">independent</font>  drug  stores  and  small  chains  has <font color="blue">decreased as retail</font>     <font color="blue">consolidation</font> has occurred</td>
    </tr>
    <tr>
      <td>Further <font color="blue">consolidation</font> among, or any financial     <font color="blue"><font color="blue">difficult</font>ies</font> of, <font color="blue">distributor</font>s or retailers could result in the <font color="blue">combination</font>     or <font color="blue">elimination</font> of warehouses, which may result in <font color="blue">reductions</font> in purchases of     our products, returns of our products, or cause a reduction in the inventory     levels of <font color="blue">distributor</font>s and retailers, any of <font color="blue">which could</font> have a material     adverse <font color="blue">impact on</font> our business</td>
    </tr>
    <tr>
      <td>If we lose any of these <font color="blue">customer accounts</font>,     or if our <font color="blue">relationship with them</font> were to <font color="blue">deteriorate</font>, our business could     also be <font color="blue">materially</font> and <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Our revenues <font color="blue">depend on</font> payment and <font color="blue">reimbursement</font> from <font color="blue">third party</font> payors,     and if they reduce or <font color="blue">refuse payment</font> or <font color="blue">reimbursement</font>, the use and sales of     our <font color="blue">products will suffer</font>, we may not increase our market share, and our     revenues and <font color="blue">profitability</font> will suffer</td>
    </tr>
    <tr>
      <td>Our operating results and business <font color="blue">success depend</font>, in part, on whether     adequate  <font color="blue">reimbursement</font>  is  available  for the use of our <font color="blue">products by</font>     hospitals, clinics, doctors and patients</td>
    </tr>
    <tr>
      <td>Third-party payors include state     and  federal  programs  such  as  Medicare  and Medicaid, <font color="blue">managed care</font>     <font color="blue">organizations</font>, private insurance plans and <font color="blue">health maintenance <font color="blue">organizations</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>of the size of the patient population covered by <font color="blue">managed care</font>     <font color="blue">organizations</font>, it is important to our business that we market our products     to  them and to the <font color="blue">pharmacy benefit managers</font> that serve many of these     <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>If only a portion of the cost of our <font color="blue"><font color="blue">prescription</font> products</font> is     paid  for or reimbursed, our <font color="blue">products could</font> be less attractive, from a     net-cost perspective, to patients, suppliers and <font color="blue">prescribing physicians</font></td>
    </tr>
    <tr>
      <td><font color="blue">Managed  </font>care <font color="blue">organizations</font> and other third-party payors try to     negotiate the pricing of <font color="blue">medical services</font> and products to control their     costs</td>
    </tr>
    <tr>
      <td>Managed care <font color="blue">organizations</font> and <font color="blue">pharmacy benefit managers</font> typically     develop <font color="blue">formularies</font> to reduce their cost for <font color="blue">medications</font></td>
    </tr>
    <tr>
      <td><font color="blue">Formularies </font>can be     <font color="blue">based on</font> the prices and <font color="blue">therapeutic benefits</font> of the <font color="blue">available products</font></td>
    </tr>
    <tr>
      <td>Due     to their <font color="blue">lower cost</font>s, generics are often favored on <font color="blue">formularies</font></td>
    </tr>
    <tr>
      <td>The breadth     of the products covered by <font color="blue">formularies</font> varies considerably from one managed     <font color="blue">care organization</font> to another, and many <font color="blue">formularies</font> include <font color="blue">alternative</font> and     <font color="blue">competitive</font> products for treatment of <font color="blue">particular medical conditions</font></td>
    </tr>
    <tr>
      <td>In some     cases, third-party payors will pay or <font color="blue">reimburse users</font> or suppliers of a     <font color="blue"><font color="blue">prescription</font> drug product only</font> a portion of the <font color="blue">product purchase price</font></td>
    </tr>
    <tr>
      <td><font color="blue">Consumers </font>and third-                                         25       _________________________________________________________________    [103]Table <font color="blue">of <font color="blue">Contents       </font></font><font color="blue">party payors may</font> not view our <font color="blue">marketed products</font> as cost-<font color="blue">effective</font>, and     <font color="blue">consumers may</font> not be able to get <font color="blue">reimbursement</font> or <font color="blue">reimbursement</font> may be so     low that we <font color="blue">cannot market</font> our <font color="blue">products on</font> a <font color="blue">competitive</font> basis</td>
    </tr>
    <tr>
      <td>If a product     is  excluded from a formulary, its usage may be sharply reduced in the     managed  <font color="blue">care organization</font> patient population</td>
    </tr>
    <tr>
      <td>If our products are not     included within an adequate number of <font color="blue">formularies</font> or adequate <font color="blue">reimbursement</font>     levels are not provided, or if those <font color="blue">policies increasingly favor generic</font>     products, our market share and gross <font color="blue">margins could</font> be <font color="blue">negatively</font> affected,     as could our overall business and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We take reserves for     the estimated amounts of rebates we will pay to <font color="blue">managed care</font> <font color="blue">organizations</font>     each  quarter</td>
    </tr>
    <tr>
      <td>Any increase in returns and any <font color="blue">increased usage</font> of our     <font color="blue">products through</font> Medicaid or <font color="blue">managed care</font> programs will affect the amount of     rebates that we owe</td>
    </tr>
    <tr>
      <td>Our <font color="blue">continued growth depends on</font> our ability to develop <font color="blue">new products</font>, and if     we are unable to develop <font color="blue">new products</font>, our <font color="blue">expenses may exceed</font> our revenues     without any return on the <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We currently have a variety of <font color="blue">new products</font> in <font color="blue">various stages</font> of     research  and  <font color="blue">development</font>  and  are working <font color="blue">on possible improvements</font>,     <font color="blue">extensions</font> and <font color="blue">reformulations</font> of some <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>These research and     <font color="blue">development</font> activities, as well as the <font color="blue">clinical testing</font> and <font color="blue">regulatory</font>     approval process, will require <font color="blue">significant</font> <font color="blue">commitment</font>s of personnel and     financial  resources</td>
    </tr>
    <tr>
      <td>Delays in the research, <font color="blue">development</font>, testing or     <font color="blue">approval processes will</font> cause a <font color="blue">corresponding delay</font> in the <font color="blue">commencement</font> of     <font color="blue">revenue generation from</font> those products</td>
    </tr>
    <tr>
      <td>We re-evaluate our research and <font color="blue">development</font> efforts regularly to     <font color="blue">assess whether</font> our efforts to develop a <font color="blue">particular product</font> or <font color="blue">technology</font> are     progressing at a rate that justifies our <font color="blue">continued expenditures</font></td>
    </tr>
    <tr>
      <td>On the     basis  of these re-evaluations, we have abandoned in the past, and may     abandon in the future, our <font color="blue">efforts on</font> a <font color="blue">particular product</font> or <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Products we are <font color="blue">researching</font> or developing may never be <font color="blue">successfully released</font>     to the market and, <font color="blue">regardless</font> of whether we <font color="blue">ever release them</font> to the market,     we <font color="blue">will already</font> have incurred the expense of <font color="blue">such processes</font></td>
    </tr>
    <tr>
      <td>If we do not successfully integrate <font color="blue">new products</font> into our business, we may     not be able to <font color="blue">sustain revenue growth</font> and we may not be able to compete     <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>When we acquire or develop <font color="blue">new products</font> and <font color="blue">product lines</font>, we must be     able to integrate those products and <font color="blue">product lines</font> into our systems for     marketing, sales and <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>If we do not integrate these products or     <font color="blue">product lines</font> successfully, the potential for growth is limited</td>
    </tr>
    <tr>
      <td>The new     products  we  acquire  or develop could have channels of <font color="blue">distribution</font>,     <font color="blue">competition</font>, price limitations or <font color="blue">marketing <font color="blue">acceptance</font> different from</font> our     <font color="blue">current products</font></td>
    </tr>
    <tr>
      <td>As a result, we do not know whether we will be able to     compete  <font color="blue">effective</font>ly  or  obtain  <font color="blue">market <font color="blue">acceptance</font></font> in any new product     <font color="blue">categories</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">new product may</font> require us to <font color="blue">significant</font>ly increase our sales     force and incur additional marketing, <font color="blue">distribution</font> and other operational     expenses</td>
    </tr>
    <tr>
      <td>These additional expenses could <font color="blue">negatively</font> affect our gross     margins and operating results</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">could incur</font> many of these     expenses before the actual <font color="blue">distribution</font> of <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>Because of this     timing, if the market does not accept the <font color="blue">new products</font>, or if they are not     <font color="blue">competitive</font>  with similar products <font color="blue">distributed</font> by others, the ultimate     success of the <font color="blue">acquisition</font> or <font color="blue">development</font> could be <font color="blue"><font color="blue">substantially</font> diminished</font></td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">third parties</font> to conduct <font color="blue"><font color="blue">clinical trial</font>s</font> for our product     <font color="blue">candidates</font>, and those <font color="blue">third parties</font> may not perform <font color="blue">satisfactorily</font></td>
    </tr>
    <tr>
      <td>If those     <font color="blue">third parties</font> do not perform <font color="blue">satisfactorily</font>, it may <font color="blue">significant</font>ly delay     <font color="blue">commercialization</font> of our products, increase expenditures and <font color="blue">negatively</font>     affect our prospects for <font color="blue">future revenue growth</font></td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">third parties</font> to <font color="blue">independent</font>ly conduct clinical studies for     our  product  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If  these  third  parties  do  not  perform     <font color="blue">satisfactorily</font>, we may not be able to locate acceptable <font color="blue">replacements</font> or     <font color="blue">enter into</font> favorable <font color="blue">agreements</font> with them</td>
    </tr>
    <tr>
      <td>If we are unable to rely on     <font color="blue">clinical data collected by others</font>, we                                         26       _________________________________________________________________    [104]Table <font color="blue">of <font color="blue">Contents       </font></font>could be required to repeat, extend the duration of, or increase the size     of, <font color="blue"><font color="blue">clinical trial</font>s</font>, <font color="blue">which could</font> <font color="blue">significant</font>ly delay required <font color="blue">regulatory</font>     approvals and require <font color="blue">significant</font>ly greater expenditures</td>
    </tr>
    <tr>
      <td>We rely on the services of a <font color="blue">single company</font> to distribute our products to     our customers</td>
    </tr>
    <tr>
      <td>A delay or <font color="blue">interruption</font> in the <font color="blue">distribution</font> of our products     could <font color="blue">negatively</font> impact our business</td>
    </tr>
    <tr>
      <td>SPS handles all of our product <font color="blue">distribution</font> activities</td>
    </tr>
    <tr>
      <td>SPS stores and     <font color="blue">distributes</font>  our  <font color="blue">products from</font> a warehouse in Tennessee</td>
    </tr>
    <tr>
      <td>Any delay or     <font color="blue">interruption</font> in the process or in <font color="blue">payment could</font> result in a delay delivering     product to our customers, <font color="blue">which could</font> have a <font color="blue">significant</font> negative <font color="blue">impact on</font>     our business</td>
    </tr>
    <tr>
      <td>Risks Related to Our Industry       We face intense <font color="blue">competition</font>, which may limit our <font color="blue">commercial opportunities</font>     and limit our ability to <font color="blue">generate revenues</font></td>
    </tr>
    <tr>
      <td>The  specialty  <font color="blue">pharmaceutical</font>  industry is highly <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in our industry occurs on many fronts, including developing and     bringing <font color="blue">new products</font> to market before others, developing new <font color="blue">technologies</font>     to improve <font color="blue">existing products</font>, developing <font color="blue">new products</font> to provide the same     benefits as <font color="blue">existing products</font> at less cost, developing <font color="blue">new products</font> to     provide benefits superior to those of <font color="blue">existing products</font>, and acquiring or     licensing <font color="blue">complementary</font> or novel <font color="blue">technologies</font> from other <font color="blue">pharmaceutical</font>     companies or <font color="blue">individuals</font></td>
    </tr>
    <tr>
      <td>Most of our <font color="blue">competitors</font> are large, well-established companies in the     fields of <font color="blue">pharmaceutical</font>s and <font color="blue">health care</font></td>
    </tr>
    <tr>
      <td>Many of these companies have     <font color="blue">substantially</font> greater financial, technical and human resources than we have     to devote to marketing, sales, research and <font color="blue">development</font> and <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may develop or acquire new or <font color="blue">improved products</font> to treat the     <font color="blue">same conditions as</font> our <font color="blue">products treat</font>, or may make <font color="blue">technological advances</font>     that  reduce their cost of production so that they may engage in price     <font color="blue">competition</font> through aggressive <font color="blue">pricing policies</font> to secure a <font color="blue">greater market</font>     share to our detriment</td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial opportunities</font> will be reduced or     eliminated if our <font color="blue">competitors</font> develop or acquire and <font color="blue">market products</font> that     are more <font color="blue">effective</font>, have fewer or <font color="blue">less severe adverse</font> side effects, or are     <font color="blue">less expensive than</font> our products</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>also may develop or acquire     products that make our current or <font color="blue">future products obsolete</font></td>
    </tr>
    <tr>
      <td>Any of these     events  could  have  a <font color="blue">significant</font> negative <font color="blue">impact on</font> our business and     financial  results, including <font color="blue">reductions</font> in our market share and gross     margins</td>
    </tr>
    <tr>
      <td>Luxiq  Foam,  OLUX  Foam  and <font color="blue">Evoclin Foam </font><font color="blue">compete with generic</font>     <font color="blue">pharmaceutical</font>s, which claim to <font color="blue">offer equivalent benefit at</font> a <font color="blue">lower cost</font></td>
    </tr>
    <tr>
      <td>In     some cases, insurers and other <font color="blue">health care</font> payment <font color="blue">organizations</font> encourage     the use of these <font color="blue">less expensive generic brands through</font> their <font color="blue">prescription</font>     <font color="blue">benefits coverage</font> and <font color="blue">reimbursement</font> policies</td>
    </tr>
    <tr>
      <td>These <font color="blue">organizations</font> may make     the  generic  <font color="blue">alternative</font>  more attractive to the patient by providing     <font color="blue">different amounts</font> of <font color="blue">reimbursement</font> so that the net cost of the generic     product to the patient is less than the net cost of our <font color="blue">prescription</font> brand     product</td>
    </tr>
    <tr>
      <td><font color="blue">Aggressive </font><font color="blue"><font color="blue">pricing policies</font> by</font> our generic product <font color="blue">competitors</font> and     the <font color="blue">prescription</font> benefits policies of <font color="blue">insurers could</font> cause us to <font color="blue">lose market</font>     share or force us to reduce our margins in response</td>
    </tr>
    <tr>
      <td>The growth of <font color="blue">managed care</font> <font color="blue">organizations</font> and other third-party <font color="blue">reimbursement</font>     policies and state <font color="blue">regulatory</font> agencies may have an adverse effect on our     <font color="blue">pricing policies</font> and our margins</td>
    </tr>
    <tr>
      <td>Federal and state <font color="blue">regulations</font> govern or influence the <font color="blue">reimbursement</font> to     health  care providers of fees in <font color="blue"><font color="blue">connection</font> with</font> medical treatment of     certain patients</td>
    </tr>
    <tr>
      <td>In the US, there have been, and we expect <font color="blue">there will</font>     continue to be, a number of state and <font color="blue">federal proposals</font> that <font color="blue">could limit</font> the     amount that state or <font color="blue">federal governments will pay</font> to reimburse the cost of     drugs</td>
    </tr>
    <tr>
      <td><font color="blue">Continued </font><font color="blue">significant</font> changes in the <font color="blue">health care</font> system could have a     <font color="blue">significant</font> negative <font color="blue">impact on</font> our business</td>
    </tr>
    <tr>
      <td>We believe the increasing     emphasis on <font color="blue">managed care</font> in the US <font color="blue">will continue</font> to <font color="blue">put pressure on</font> the     price and usage of our products, which may in turn <font color="blue">adversely</font> impact product     sales</td>
    </tr>
    <tr>
      <td>Changes in <font color="blue">reimbursement</font> policies or <font color="blue">health care</font> cost <font color="blue">containment</font>     <font color="blue">initiatives</font> that limit or restrict <font color="blue">reimbursement</font> for our products may cause     our revenues to decline</td>
    </tr>
    <tr>
      <td>27       _________________________________________________________________    [105]Table <font color="blue">of <font color="blue">Contents       </font></font>      In recent years, various <font color="blue">legislative</font> proposals have <font color="blue">been offered</font> in     <font color="blue">Congress </font>and in some state <font color="blue">legislatures</font> that include major changes in the     health  care  system</td>
    </tr>
    <tr>
      <td>These  proposals have included price or patient     <font color="blue">reimbursement</font> constraints on medicines and <font color="blue">restrictions</font> on access to certain     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the outcome of such <font color="blue">initiatives</font>, and it is     <font color="blue">difficult</font> to predict the <font color="blue">future impact</font> to us of the broad and expanding     <font color="blue">legislative</font> and <font color="blue">regulatory</font> <font color="blue">requirements</font> that may apply to us</td>
    </tr>
    <tr>
      <td>Our industry is subject to extensive <font color="blue">governmental regulation</font></td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">must approve</font> a drug before it can be sold in the <font color="blue">US In     </font>addition,  the  Federal Food, Drug and Cosmetic Act, the Federal Trade     Commission, Office of the Inspector General and other federal and state     agencies,  statutes, and <font color="blue">regulations</font> govern the safety, <font color="blue">effective</font>ness,     testing, <font color="blue">manufacture</font>, labeling, storage, record keeping, approval, sampling,     <font color="blue">advertising</font> and promotion of <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td><font color="blue">Complying </font>with the     mandates of these agencies, statutes and <font color="blue">regulations</font> is expensive and time     consuming, and adds <font color="blue">significant</font>ly to the cost of developing, <font color="blue">manufacturing</font>     and marketing our products</td>
    </tr>
    <tr>
      <td>In addition, failure to <font color="blue">comply with</font> applicable     agency, statutory and <font color="blue">regulatory</font> <font color="blue">requirements</font> could, among other things,     result in:         •  fines or other civil or <font color="blue">criminal sanctions</font>,         •  delays in product <font color="blue">development</font>, <font color="blue">distribution</font>, marketing and sale,         •  denials or <font color="blue">suspensions</font> of <font color="blue"><font color="blue">regulatory</font> approvals</font> of our products, and         •  recalls of our products</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">product <font color="blue">liability</font></font> lawsuits</font> are <font color="blue">brought against us</font>, we may incur     substantial costs</td>
    </tr>
    <tr>
      <td>Our industry faces an <font color="blue">inherent risk</font> of <font color="blue">product <font color="blue">liability</font></font> claims from     <font color="blue">allegations</font> that our products resulted in <font color="blue">adverse effects</font> to patients or     others</td>
    </tr>
    <tr>
      <td>These risks exist <font color="blue">even with respect</font> to those products that are     approved for <font color="blue">commercial sale by</font> the FDA and <font color="blue">manufacture</font>d in <font color="blue">facilities</font>     licensed and regulated by <font color="blue">the FDA In March </font>2004, we acquired exclusive     US rights to Soriatane, which is a <font color="blue">product known</font> to cause serious birth     defects  and other serious side effects</td>
    </tr>
    <tr>
      <td>We maintain <font color="blue">product <font color="blue">liability</font></font>     insurance in the amount of dlra15 million aggregate, which may not provide     adequate coverage against potential <font color="blue">product <font color="blue">liability</font></font> claims or losses</td>
    </tr>
    <tr>
      <td>Insurers have <font color="blue">been less willing</font> to extend <font color="blue">product <font color="blue">liability</font></font> insurance for     Soriatane, and that insurance is only available at higher premiums and with     higher  <font color="blue">deductibles</font> than our other products require</td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot</font> be     certain that our current coverage <font color="blue">will continue</font> to be available in the     <font color="blue">future on reasonable terms</font>, if at all</td>
    </tr>
    <tr>
      <td>If we were <font color="blue">found liable</font> for any     product  <font color="blue">liability</font>  claims in excess of our coverage or outside of our     coverage, the cost and expense of such <font color="blue">liability</font> could severely damage our     business, <font color="blue">financial condition</font> and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">market price</font>s</font> for securities of specialty <font color="blue"><font color="blue">pharmaceutical</font> companies</font>     like ours have been and are likely to continue to be <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>As a     result, investors in these companies often buy at very high prices only to     see the price drop <font color="blue">substantially</font> a short time later, resulting in an extreme     drop  in  value  in  the  holdings of these investors</td>
    </tr>
    <tr>
      <td>Factors such as     <font color="blue">announcements</font> of <font color="blue">fluctuations</font> in our or our <font color="blue">competitors</font>’ operating results,     changes in our prospects and <font color="blue">general <font color="blue">market conditions</font></font> for <font color="blue">pharmaceutical</font>     bio<font color="blue">technology</font> stocks could have a <font color="blue">significant</font> <font color="blue">impact on</font> the <font color="blue">future trading</font>     prices of our <font color="blue">common stock</font> and the notes</td>
    </tr>
    <tr>
      <td>In particular, the <font color="blue">trading price</font>     of the <font color="blue">common stock</font> of many <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies,     including us, has experienced <font color="blue">extreme price</font> and volume <font color="blue">fluctuations</font>, which     have <font color="blue">at times been unrelated</font> to the operating performance of the companies     <font color="blue">whose stocks</font> were affected</td>
    </tr>
    <tr>
      <td>Some of the factors that may cause <font color="blue">volatility</font> in     the price of our securities include:         •  <font color="blue">clinical trial</font> results and <font color="blue">regulatory</font> <font color="blue">development</font>s,         •  <font color="blue">quarterly variations</font> in results,                                         28       _________________________________________________________________    [106]Table <font color="blue">of <font color="blue">Contents       </font></font>  •  the timing of new product <font color="blue">introductions</font>,         •  <font color="blue">competition</font>, including both branded and generic,         •  business and product market cycles,         •  <font color="blue">fluctuations</font> in customer <font color="blue">requirements</font>,         •  the <font color="blue">availability</font> and <font color="blue">utilization</font> of <font color="blue">manufacturing</font> <font color="blue">capacity</font>,         •  our ability to develop and implement new <font color="blue">technologies</font>,         •  the timing and amounts of royalties paid to us by <font color="blue">third parties</font>, and         •  issues with the safety or <font color="blue">effective</font>ness of our products</td>
    </tr>
    <tr>
      <td>The price of our <font color="blue">common stock</font> may also be <font color="blue">adversely</font> <font color="blue">affected by</font> the     estimates and <font color="blue">projections</font> of the <font color="blue">investment</font> community, general economic and     <font color="blue">market conditions</font>, and the cost of <font color="blue">operations</font> in our <font color="blue">product markets</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>factors,  either  individually  or  in  the aggregate, could result in     <font color="blue">significant</font> variations in the <font color="blue">trading price</font>s of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Volatility     </font>in the <font color="blue">trading price</font>s of our <font color="blue">common stock</font> could result in securities class     <font color="blue">action litigation</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation would likely</font> result in substantial costs,     and divert our <font color="blue">management</font>’s attention and resources</td>
    </tr>
    <tr>
      <td>The <font color="blue">following table sets forth</font> the high and low closing <font color="blue">sale prices</font> of     our <font color="blue">common stock</font> on the <font color="blue">Nasdaq National Market </font>for 2005 and 2004:                                    Period   High   Low       2005                                 $ 28dtta99     $ 12dtta00       2004                                 $ 29dtta92     $ 17dtta69</td>
    </tr>
  </tbody>
</table>